Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study
详细信息 查看全文
- 作者：Luca Quartuccioa ; b ; Francesca Zulianib ; Laura Corazzab ; Patrizia Scainic ; Roberta Zanic ; Marco Lenzid ; Antonio Tavonie ; Marco Sebastianif ; Simone Baldovinog ; Teresa Urraroh ; Francesco Saccardoi ; Costanza Sbregliaj ; Cesare Mazzarok ; Piero Pioltellil ; Paolo Fraticellim ; Davide Filippinin ; Armando Gabriellim ; Oreste Perrellaj ; Salvatore Scarpatoo ; Dario Roccatellog ; Anna Linda Zignegoh ; Clodoveo Ferrif ; Stefano Bombardierie ; Maurizio Pietrograndep ; Giuseppe Montii ; Massimo Galliq ; Salvatore De Vitaa ; b ; devita.salvatore@aoud.sanita.fvg.it" class="auth_mail" title="E-mail the corresponding author
- 关键词：Vasculitis ; Cryoglobulinemia ; Rituximab ; Hepatitis
- 刊名：Journal of Autoimmunity
- 出版年：2015
- 出版时间：September 2015
- 年：2015
- 卷：63
- 期：Complete
- 页码：88-93
- 全文大小：433 K
文摘
- •
Rituximab retreatment at clinical relapse appears useful in the long term for severe cryoglobulinemic vasculitis.
- •
Rituximab retreatment at clinical relapse is associated with a low incidence of severe hypogammaglobulinemia.
- •
Rituximab retreatment at clinical relapse saves on the use of glucocorticoids in severe cases of cryoglobulinemic vasculitis.